Lastly, we revealed that mt-e-CAFs provide cancer cells with stromal cues to delay and reduce response to gemcitabine/Abraxane, which could be reverted by reducing HSPG2 stromal deposition for mt-CCs (Fig. 9f (iv)). Here, HSPG2 is linked to cancer.